The continuous evolution of respiratory therapeutics has placed renewed emphasis on developing noninvasive strategies capable of delivering biologics directly to the lungs. 

Within biologics, monoclonal antibodies are particularly well suited for this purpose because they can selectively modulate complex immunological pathways implicated in asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, viral disease, and other inflammatory airway conditions, as well as key pathways involved in oncology. 

Read the full white paper